An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

  • Moore, Maggie (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date23/04/25 → 22/04/27

Keywords

  • Clinical Trials
  • CECI830A12101